About SpineThera
SpineThera is a Healthcare company based in Plymouth (United States) founded in 2012 by Jeff Missling, and was acquired by Purdue Pharma in October 2018. Injectable drugs for back pain are developed using sustained-release technology. SpineThera has raised $11.53 million across 10 funding rounds from investors including U.S Army, Purdue Pharma and U.S. Department of Defense. The company has 6 employees. Its chief executive, as recorded, is Jeff Missling. SpineThera offers products and services including SX600 and Faros Technology. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is SpineThera, Inc. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
SpineThera was founded in 2012 in Plymouth, United States, as a biotechnology firm focused on the pharmaceutical sector. Injectable treatments for back pain are developed, with the lead candidate featuring a patent-protected sustained-release mechanism for an anti-inflammatory steroid. This approach is designed to decrease the need for frequent epidural injections. Operations center on drug development, with clinical advancement targeted at pain management solutions in the United States.
- Headquarters Plymouth, United States
- Employees 6
- Founders Jeff Missling
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website spinethera.com
- Social LinkedIn X
- Acquired by Purdue Pharma (Oct 2018)
- Legal Name Spinethera, Inc.
- Total Equity Funding$11.53M (USD)
in 10 rounds
- Latest Funding Round$4.97M (USD), Grant
Apr 2022
- InvestorsU.S Army
& 2 more
- Employee Count6
- Acquired byPurdue Pharma
(Oct 2018)
Products & Services of SpineThera
SpineThera offers a comprehensive portfolio of products and services, including SX600 and Faros Technology.
Sustained-release dexamethasone for sciatica pain relief via injection.
Enables months-long drug release in pain treatments.
Funding Insights of SpineThera
SpineThera has successfully raised a total of $11.53M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $4.97 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.53M
- Total Rounds 10
- Last Round Grant — $4.97M
- First Round $585,070
(May 2014)
- Investors Count 2
All 10 funding rounds of SpineThera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $4.97M | Grant | – | – | |
| Jun 2021 | $1.22M | Series A | – | – | – |
| Jun 2021 | Debt – Conventional | – | – | – | |
| Nov 2018 | $2M | Series A | – | – | – |
| Feb 2018 | $2.01M | Series A | – | – | – |
| Mar 2017 | $2M | Grant | – | – | |
| Feb 2017 | $2.97M | Series A | – | – | – |
| Sep 2015 | $400,025 | Series A | – | – | – |
| Aug 2015 | $2.36M | Series A | – | – | – |
| May 2014 | $585,070 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in SpineThera
SpineThera has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include U.S Army, Purdue Pharma and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Land-based military forces are organized and deployed for national defense. | 1775 | army.mil | ||
Pain-relief drugs are developed by the private pharmaceutical company. | 1892 | purduepharma.com | Stamford, United States |
Investor details for SpineThera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SpineThera
8 people are tracked at SpineThera (4 in leadership, 3 in board & advisors, 1 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Jeff Missling | Founder & CEO | Leadership |
William Houghton | Chief Medical Officer | Leadership |
Mark Payne | Chief Financial Officer | Leadership |
Jeffrey Missling | CEO & Chairman | Leadership |
Jerome K. Jerome | Board Member | Board & advisors |
Wayne Kelly | Board Member | Board & advisors |
John Foster | Board Member | Board & advisors |
Louretta Dwyer | Clinical Operations Associate | Team |
Complete people profiles for SpineThera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SpineThera
4 dated milestones of SpineThera across 10 years, from founding to its latest funding, stage changes and deals.
- Founded SpineThera is founded.
- Funding First funding round of $585K.
- Exit Acquired by Purdue Pharma.
- Funding Latest funding round, Grant, of $5.0M.
Competitors of SpineThera
SpineThera has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of SpineThera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as SpineThera (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Spinethera
Complete news archive for SpineThera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SpineThera
SpineThera was founded in 2012 and raised its 1st funding round 2 years after it was founded.
SpineThera is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Jeff Missling is the CEO of SpineThera, as recorded in our data. They have also founded this company.
SpineThera is a funded company, having raised a total of $11.53M across 10 funding rounds to date. The company's 1st funding round was a Seed of $585.07K, raised on May 2014.
SpineThera has 6 employees.
SpineThera was founded in 2012 in Plymouth, United States, as a biotechnology firm focused on the pharmaceutical sector. Injectable treatments for back pain are developed, with the lead candidate featuring a patent-protected sustained-release mechanism for an anti-inflammatory steroid. This approach is designed to decrease the need for frequent epidural injections. Operations center on drug development, with clinical advancement targeted at pain management solutions in the United States.
SpineThera's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
SpineThera offers SX600 and Faros Technology.
SpineThera has 3 investors. Key investors include U.S Army, Purdue Pharma, and U.S. Department of Defense.
SpineThera operates through Spinethera, Inc..
Yes. SpineThera was acquired by Purdue Pharma in October 2018.